DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Talazoparib tosylateis the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Talazoparib tosylate has ninety patent family members in thirty countries.
Two suppliers are listed for this compound.
Recent Clinical Trials for talazoparib tosylate
Identify potential brand extensions & 505(b)(2) entrants
|Stanford University||Phase 2|
|M.D. Anderson Cancer Center||Phase 1|
Pharmacology for talazoparib tosylate
|Drug Class||Poly(ADP-Ribose) Polymerase Inhibitor |
|Mechanism of Action||Poly(ADP-Ribose) Polymerase Inhibitors |
|Country||Patent Number||Estimated Expiration|
|Russian Federation||2011108493||⤷ Free Forever Trial|
|European Patent Office||2326650||⤷ Free Forever Trial|
|Slovenia||2767537||⤷ Free Forever Trial|
|Netherlands||301021||⤷ Free Forever Trial|
|Israel||271497||⤷ Free Forever Trial|
|World Intellectual Property Organization (WIPO)||2010017055||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|2767537||132019000000153||Italy||⤷ Free Forever Trial||PRODUCT NAME: TALAZOPARIB(TALZENNA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1377, 20190624|
|2767537||2019/060||Ireland||⤷ Free Forever Trial||PRODUCT NAME: TALAZOPARIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT.; NAT REGISTRATION NO/DATE: EU/1/19/1377/001 EU/1/19/1377/006 20190620; FIRST REGISTRATION NO/DATE: EU/1/19/1377/001 EU/1/19/1377/006 20190620 (20200708)|
|2767537||CA 2019 00055||Denmark||⤷ Free Forever Trial||PRODUCT NAME: TALAZOPARIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT; REG. NO/DATE: EU/1/19/1377 20190624|
|2767537||19C1071||France||⤷ Free Forever Trial||PRODUCT NAME: TALAZOPARIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/19/1377 20190624|
|2767537||LUC00140||Luxembourg||⤷ Free Forever Trial||PRODUCT NAME: TALAZOPARIB, EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/19/1377 20190624|
|2767537||C201930072||Spain||⤷ Free Forever Trial||PRODUCT NAME: TALAZOPARIB, OPCIONALMENTE EN FORMA DE SAL FARMACEUTICAMENTE ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1377; DATE OF AUTHORISATION: 20190620; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1377; DATE OF FIRST AUTHORISATION IN EEA: 20190620|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.